SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Christopher Prentiss as Chief Financial Officer.
“I am delighted to welcome Chris to ADARx with his extensive financial experience in the pharmaceutical industry,” said Dr. Zhen Li, President, and Chief Executive officer of ADARx. “As ADARx continues to grow, our evolving leadership structure reflects the expanding development needs of our organization as we enter clinical trials. Chris’s experience in the development and launch of pharmaceutical products directly supports our goal of turning cutting-edge science into life-saving therapeutics.”
Mr. Prentiss joins ADARx as ADX-324 for the treatment of hereditary angioedema is set to start phase I clinical trials at the end of the year. ADARx has two additional drug candidates set to enter clinical trials next year and an extensive pipeline to follow.
Mr. Prentiss has over 20 years of experience in senior financial positions with public companies in the life sciences industry. Mr. Prentiss most recently served as Chief Financial Officer of Adamas Pharmaceuticals, Inc. where he was responsible for leading the finance, investor relations, and information technology functions. During his tenure, Adamas received approval for and commercialized GOCOVRI® until the Company’s acquisition by Supernus Pharmaceuticals, Inc. Previous roles include senior finance positions at biopharmaceutical companies including Adamas Pharmaceuticals, Inc., InterMune, Inc., Dynavax Technologies Corporation, and MannKind Corporation. Prior to joining the biopharmaceutical field, Mr. Prentiss was at KPMG LLP in the assurance practice. Mr. Prentiss received a Bachelor’s of Science degree in Accounting from Loyola Marymount University and a MBA from Indiana University’s Kelley School of Business. Mr. Prentiss is a CPA licensed in California.
“I am excited to join the ADARx team at this pivotal point as the company transitions into a clinical stage organization,” said Mr. Prentiss. “I am impressed with ADARx’s drug platform, and I look forward to contributing my skills and experience to ADARx and the continued growth and development of its impressive pipeline.”
About ADARx
ADARx Pharmaceuticals, Inc., located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases. ADARx lead programs are at IND-enabling stage.